Can cannabis sharpen or dull the HIV brain? new study investigates
NCT ID NCT04883255
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how cannabis ingredients (THC and CBD) affect decision-making, attention, and motivation in people with and without HIV. About 138 adults who use cannabis infrequently will take either THC, CBD, or a placebo for 5 days and complete thinking tests and brain fluid measurements. The goal is to understand how cannabis interacts with HIV and brain function, not to treat the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Early phase 1
The earliest testing in people: a first look at safety, in a very small group.
- Participants
-
About 138 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2023
- Expected to finish
-
Jun 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria 1. Aged 18-65 2. Possess the capacity to provide informed consent to a set of neurobehavioral, neuromedical and cognitive assessment procedures. Individuals unable to provide such consent will not be enrolled into the study. 3. Willing to confirm self-reported HIV using a rapid test: HIV status will be determined using the MedMira Rapid Test (Halifax, Nova Scotia, Canada). If the result differs from the participant's self-report a confirmatory Western Blot will be performed. 4. Willing to abstain from cannabis for at least 1 week prior to the baseline visit and during the study. Although there is no definitive method for determining abstinence over this period, abstinence will be confirmed as best as possible by using an oral fluid testing device (Draeger 5000) employed by law enforcement officers to detect recent cannabis use. An oral fluid value of \> 5ng suggests recent use, although in some cases it has been reported that individuals may show \> 5ng up to 20 hours after use. Thus, should the oral fluid sample indicate \> 5ng THC, the assessment may be canceled and rescheduled. Exclusion Criteria * Inability to provide informed consent * Significant chronic renal disease (unrelated to HIV), significant chronic pulmonary disease (unrelated to HIV), or Hepatitis C Virus infection * Head injury with loss of consciousness for greater than 30 minutes or resulting in neurologic complications * Seizure disorder * Demyelinating diseases or other non-HIV neurological disorders * Pregnancy * Acute or recent or previous clinically disabling stroke or previous cerebrovascular events * Lifetime history of schizophrenia or other psychotic disorders, or bipolar disorder. * Beck Depression Inventory-II (BDI-II) score is greater than or equal to 29 (severe depression) or suicidal ideas are endorsed on the BDI-II or a Center for Epidemiological Studies-Depression Scale (CES-D) subscale measuring suicidal ideation * Substance use disorder (mild, moderate or severe) within the last 12 months
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-infection are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The study's own enquiry address
This study publishes an address for enquiries. See it below .
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
UC San Diego Medical Center-Hillcrest
RECRUITINGSan Diego, California, 92103-8620, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a cancer drug flush out hidden HIV?
- Can two antibodies and a cancer drug free people with HIV from daily pills?
- Do unsuppressed HIV infections fuel new cases in ethiopia?
- A simple idea to stop STIs: send treatment home with the patient
- Can Lab-Made antibodies give HIV patients a break from daily pills?
- Can a single HIV pill tame the epidemic in africa?